Evidence map›Paper›PMID 36962727›Full record

ArticlePLOS global public health2023

"I know why I am taking this pill": Young women navigation of disclosure and support for PrEP uptake and adherence in Eastern Cape Province, South Africa.

Joseph Daniels, Lindsey De Vos, Dana Bezuidenhout, Millicent Atujuna, Connie Celum, Sybil Hosek, Linda-Gail Bekker, Andrew Medina-Marino

Full text read
In one paragraph

Article in PLOS global public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joseph DanielsEdson College of Nursing and Health Innovation, Arizona State University, Phoenix, Arizona, United States of America.ORCID https://orcid.org/0000-0002-0985-5916
Lindsey De VosResearch Unit, Foundation for Professional Development, Buffalo City Metro, Eastern Cape Province, South Africa.ORCID https://orcid.org/0000-0001-5804-7651
Dana BezuidenhoutResearch Unit, Foundation for Professional Development, Buffalo City Metro, Eastern Cape Province, South Africa.ORCID https://orcid.org/0000-0002-9492-943X
Millicent AtujunaThe Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Connie CelumDepartments of Global Health, Medicine and Epidemiology, University of Washington, Seattle, WA, United States of America.
Sybil HosekDepartments of Psychiatry and Infectious Disease, Stroger Hospital of Cook County, Chicago, IL, United States of America.
Linda-Gail BekkerThe Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
Andrew Medina-MarinoResearch Unit, Foundation for Professional Development, Buffalo City Metro, Eastern Cape Province, South Africa.ORCID https://orcid.org/0000-0002-2691-982X

Funding

The Community PrEP StudyR01MH114648 · NIMH · FOUNDATION FOR PROFESSIONAL DEVELOPMENT · PI BEKKER, LINDA-GAIL GAIL, MEDINA-MARINO, ANDREW · 2017 to 2021
$2.4M
Social Determinants of HIVT32MH128395 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Gina Maria Wingood · 2021 to 2026
$1.4M
NIMH NIH HHS R01 MH114648NIMH NIH HHS T32 MH128395
6 · The paper itself

Abstract

There is limited understanding of the dynamic interplay between adolescent girl's and young women's (AGYW) disclosure and social support for using oral pre-exposure prophylaxis (PrEP) and adherence. Towards this, we conducted interviews with 42 AGYW enrolled in The Community PrEP Study who exhibited either high or low blood concentrations of tenofovir-diphosphate (TFV-DP) in dried blood spots. Guided by Theories of Practice, interviews and analysis focused on AGYW perspectives and experiences with PrEP disclosure, support and adherence. AGYW with high TFV-DP blood concentrations described larger social support networks and disclosure events. In contrast, those with low TFV-DP blood concentrations described disclosing to fewer people, resulting in limited social support. Participants discussed partner support, however, this support was not described as consequential to adherence, irrespective of TFV-DP levels. Those with high levels of TFV-DP in their blood described the ability to navigate social scrutiny and changes in social support, while those with low levels of TFV-DP in their blood were more likely to question their own continued use of PrEP. To facilitate AGYW's prevention-effective use of PrEP, expanded skill-building for disclosure and resiliency against changes to social support should be examined as part of PrEP services.

Identifiers

PMID36962727
PMCPMC10021316

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read11
identifiers read1
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.